The pathway allows medicine developers to work with the regulators, the NHS and health technology assessment bodies.

In his first Senate confirmation hearing to be secretary of the Department of Health and Human Services, Robert F. Kennedy Jr ...

Senators had objected to the financial conflict posed by Robert F. Kennedy Jr.’s decision to retain a financial stake in ...

A groundbreaking approach led by a team of scientists, including Rice University chemist James Tour, has the potential to ...

AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

After the Red No. 3 ban, there are now eight color additives approved by the FDA. They are FD&C Blue No. 1, FD&C Blue No. 2, ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

If confirmed as health secretary, Robert F. Kennedy Jr. would oversee the Food and Drug Administration and other agencies ...

Trump's pick for HHS Secretary faces questions from the left and right over his health stances. But will that stop his ...

In this week’s edition of InnovationRx, we look at HHS nominee Robert F. Kennedy Jr.’s first Senate confirmation hearing, the ...